Start here if you're new
what it is
Finch tries to monetize microbiome patents, licensing, and litigation after winding down most drug work.
how it gets paid
Last year Finch Therapeutics made $100K in revenue. IP licensing was the main engine at $0M, or 25% of sales.
what just happened
Revenue stayed at $0 while EPS fell to -$5.42.
At a glance
n/a balance sheet
-$8.64 fy2024 eps est
$0M fy2023 rev est
1.2 beta
~$21M market cap
xvary composite: 18/100 — weak
What they do
Finch tries to monetize microbiome patents, licensing, and litigation after winding down most drug work.
Finch has $0 revenue and 1 employee. That is not a commercial engine; it is a legal wrapper around patents and samples. You are betting that licensing or litigation can pay more than the company costs to exist.
How they make money
$100K
annual revenue
IP licensing
$0M
Patent enforcement
$0M
Academic collaborations
$0M
Asset disposition
$0M
The products that matter
lead clinical candidate
CP101
$100K collaboration revenue baseline
it is the lead asset in a company with $100K of collaboration revenue and no approved-product sales. if CP101 slips, most of the equity case slips with it.
main asset
microbiome discovery platform
Human-First Discovery Platform
$16M cash backing as of june 2024
the platform matters if it produces a partnerable program. right now it sits inside a company with $16M in cash, so time is part of the thesis.
ip engine
Key numbers
$21M
market cap
The whole company trades like a tiny asset, not a drug winner.
$16.0M
cash
This is the runway number. On $0 revenue, cash is the only clock.
-$5.42
latest eps
That loss is the cost of keeping a nearly empty company alive.
1
employee
One employee means almost no operating cushion.
Financial health
n/a
strength
- balance sheet grade n/a
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
n/a — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for FNCH right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue stayed at $0 while EPS fell to -$5.42.
Finch has scaled back clinical work and now points to IP, patents, and collaborations. That leaves the quarter tied to cash preservation, not product sales.
$0M
revenue
-$5.42
eps
n/a
n/a
revenue
Revenue was $0, so the business produced no top line to absorb losses.
source: SEC filing, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk is clinical failure or delay for CP101 — when one asset carries most of the equity story, bad data does not hurt the thesis, it erases it.
med
cash runway keeps shrinking
Finch had $16M in cash as of june 2024 and $100K of collaboration revenue. That means time is being funded, not growth.
If cash steps down and no financing or partnership shows up, the next capital raise starts from weakness.
med
CP101 is the whole board
This is a single-asset setup in practice. There is no marketed product base to cushion a failed trial or regulatory setback.
A clinical miss would remove the main reason the market assigns value beyond cash and residual IP.
med
delisting makes financing harder
The planned Nasdaq delisting process, including a Form 25 filing expected around October 2024, puts liquidity at risk.
A thinner market can widen spreads, cut investor access, and push the cost of capital higher.
med
outside interest may never show up
The catch: $100K of collaboration revenue is not proof that the platform attracts real partner demand.
If no partner or investor puts real dollars behind the science, the stock keeps trading like cash plus doubt.
$16M in cash is supporting a company with $100K of collaboration revenue and one lead asset. That is a small margin for error.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next reported update
Mar 27, 2026 is the scheduled Q2 2026 earnings release. For FNCH, that means cash movement, listing status, and any CP101 signal.
listing risk
nasdaq delisting timeline
The Form 25 filing was expected around October 2024. If the listing goes, liquidity and visibility often get worse.
balance sheet
cash versus the $16M base
June 2024 cash was $16M. The next question is how much of that base is left after corporate costs and clinical work keep running.
business trend
does the platform attract outside money
$100K of collaboration revenue is not enough to call this a business line. Any real partner interest would matter because the starting point is so low.
Analyst rankings
street attention
thin
There is no deep analyst bench here. In human-speak, you are doing most of the underwriting yourself.
earnings outlook
low
A 2026 EPS outlook of -$1.75 with no real revenue base means estimates are less about forecasting a business and more about burn math.
value / income fit
fails both
No earnings, no dividend, no usable P/E. Classic ranking systems were not built for this kind of stock.
source: institutional data
Institutional activity
institutional ownership data for FNCH is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$13
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive